Lupin launches Fidia's Hyalgan in India
This article was originally published in Scrip
Executive Summary
Lupin has launched a sodium hyaluronate injection product, Hyalgan, on the Indian market for the treatment of osteoarthritis, under a licensing arrangement with Fidia. Lupin told Scrip that it has exclusive local rights to the product and would pay royalties to the Italian company, adding that the product had been test marketed over the past six months across the country. Hyalgan is believed to be priced at a discount to Genzyme's single-injection Synvisc-One (hylan G-F 20). Hyalgan is recommended for patients with stage one to three osteoarthritis to relieve the acute pain associated with the disorder. The Indian osteoarthritis market is currently valued at about Rs1.50 billion ($32.9 million), with a patient base of more than 15 million. By 2011, India is projected to have 66 million people (aged more than 65 years) in the high-risk segment for osteoarthritis.